NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Descending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
65597-0406-01 | 65597-0406 | fam-trastuzumab deruxtecan-nxki | Enhertu | 100.0 mg/5mL | Immunotherapy | Drug Antibody Conjugate | Topoisomerase I Inhibitor | Intravenous | Dec. 20, 2019 | In Use | |
51144-0003-01 | 51144-0003 | Tisotumab vedotin | TIVDAK | 40.0 mg/4mL | Immunotherapy | Drug Antibody Conjugate | Tissue factor | Intravenous | Sept. 20, 2021 | In Use | |
59572-0501-00 | 59572-0501 | Pomalidomide | Pomalyst | 1.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb. 18, 2013 | In Use | |
59572-0501-21 | 59572-0501 | Pomalidomide | Pomalyst | 1.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb. 18, 2013 | In Use | |
59572-0502-00 | 59572-0502 | Pomalidomide | Pomalyst | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb. 18, 2013 | In Use | |
59572-0502-21 | 59572-0502 | Pomalidomide | Pomalyst | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb. 18, 2013 | In Use | |
59572-0503-00 | 59572-0503 | Pomalidomide | Pomalyst | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb. 18, 2013 | In Use | |
59572-0503-21 | 59572-0503 | Pomalidomide | Pomalyst | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb. 18, 2013 | In Use | |
59572-0504-00 | 59572-0504 | Pomalidomide | Pomalyst | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb. 18, 2013 | In Use | |
59572-0504-21 | 59572-0504 | Pomalidomide | Pomalyst | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb. 18, 2013 | In Use |
Found 10,000 results in 2 milliseconds — Export these results